drugset / Trial / NCT00325169

SERETIDE Plus Tiotropium Versus Individual Components

NCT00325169

Phase 2 Completed 41 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

This study was designed to evaluate the effects on lung function of a combination of SERETIDE 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg once daily alone and SERETIDE 50/500mcg twice daily alone) in subjects with COPD. The study will utilise a three-way cross-over design with a 2-week wash-out period between each 2-week consecutive treatment period.

Timeline

Start
2005-12
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 500 ug
Subject Salmeterol Other / unclassified 50 ug
Subject Tiotropium Other / unclassified 18 ug